[
  {
    "ts": null,
    "headline": "Eli Lilly cuts surprising deals with upstart biotech players",
    "summary": "Eli Lilly stock reached a new 52-week high on Nov. 10, up 4.7% and extending a month-long rally of 16%, after the pharmaceutical giant announced two strategic deals, following the highly anticipated deal with the White House. The move underlines Eli Lilly’s ambition to expand beyond its dominant ...",
    "url": "https://finnhub.io/api/news?id=cd956b08badd2b23e2ba1ab4e31422c5021e21984a299e5ff2251690602b5319",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762819200,
      "headline": "Eli Lilly cuts surprising deals with upstart biotech players",
      "id": 137437656,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly stock reached a new 52-week high on Nov. 10, up 4.7% and extending a month-long rally of 16%, after the pharmaceutical giant announced two strategic deals, following the highly anticipated deal with the White House. The move underlines Eli Lilly’s ambition to expand beyond its dominant ...",
      "url": "https://finnhub.io/api/news?id=cd956b08badd2b23e2ba1ab4e31422c5021e21984a299e5ff2251690602b5319"
    }
  },
  {
    "ts": null,
    "headline": "Merck’s Heart Pill Slashes Cholesterol Levels in Test Patients",
    "summary": "The daily pill reduced LDL cholesterol by 56% in just six months, among patients whose LDL defy treatment with everyday statin drugs.",
    "url": "https://finnhub.io/api/news?id=cd1dcc678f221e9a9dd9e8e12e6c2121f6aed9edece2003400de7d273c796396",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762809600,
      "headline": "Merck’s Heart Pill Slashes Cholesterol Levels in Test Patients",
      "id": 137415864,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The daily pill reduced LDL cholesterol by 56% in just six months, among patients whose LDL defy treatment with everyday statin drugs.",
      "url": "https://finnhub.io/api/news?id=cd1dcc678f221e9a9dd9e8e12e6c2121f6aed9edece2003400de7d273c796396"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Advance Late Afternoon",
    "summary": "Health care stocks rose late Monday afternoon with the NYSE Health Care Index adding 0.8% and the He",
    "url": "https://finnhub.io/api/news?id=cd84ce8ffc7b66ad7fe0c88ac84d6e31fa319678011d9a0abb204b453f0b66a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762808481,
      "headline": "Sector Update: Health Care Stocks Advance Late Afternoon",
      "id": 137437658,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks rose late Monday afternoon with the NYSE Health Care Index adding 0.8% and the He",
      "url": "https://finnhub.io/api/news?id=cd84ce8ffc7b66ad7fe0c88ac84d6e31fa319678011d9a0abb204b453f0b66a8"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street is Pounding the Table Over NVDA, RUN, LLY",
    "summary": "Markets are coming back strong. All thanks to the news that the government shutdown may soon be over, which would remove a good deal of uncertainty in the markets. In fact, in the latest agreement, some Democrats and Republicans finally reached a vote of 60 to 40 to advance the vote to the next stage. ... Wall Street is Pounding the Table Over NVDA, RUN, LLY",
    "url": "https://finnhub.io/api/news?id=2098989202d7fbb0ec835b58a79524c30643bf46d851f8fe791975e35d581849",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762800338,
      "headline": "Wall Street is Pounding the Table Over NVDA, RUN, LLY",
      "id": 137437659,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Markets are coming back strong. All thanks to the news that the government shutdown may soon be over, which would remove a good deal of uncertainty in the markets. In fact, in the latest agreement, some Democrats and Republicans finally reached a vote of 60 to 40 to advance the vote to the next stage. ... Wall Street is Pounding the Table Over NVDA, RUN, LLY",
      "url": "https://finnhub.io/api/news?id=2098989202d7fbb0ec835b58a79524c30643bf46d851f8fe791975e35d581849"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly keeps up ophthalmic gene therapy push with $475m MeiraGTx deal",
    "summary": "MeiraGTx’s AAV-AIPL1 has already led to vision gains in blind children, as regulatory submissions for the gene therapy close in.",
    "url": "https://finnhub.io/api/news?id=90d3e703a74a650e59e2337aa2d16a32b9b999f2543240fa9d191b930cb9e049",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762797709,
      "headline": "Eli Lilly keeps up ophthalmic gene therapy push with $475m MeiraGTx deal",
      "id": 137396559,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "MeiraGTx’s AAV-AIPL1 has already led to vision gains in blind children, as regulatory submissions for the gene therapy close in.",
      "url": "https://finnhub.io/api/news?id=90d3e703a74a650e59e2337aa2d16a32b9b999f2543240fa9d191b930cb9e049"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock on Pace for a New High. The Zepbound Maker Just Got a Big Upgrade.",
    "summary": "Shares of  Eli Lilly  have not only bounced back from last week’s lows but have also surged to new highs as Wall Street digs into the implications of the company’s deal with the U.S. government.  Lilly stock was up 4.8% at $969.14, putting it on pace for a record closing high, according to Dow Jones Market Data.  Leerink Partners analyst David Risinger upgraded shares to Outperform from Market Perform and raised his price target to $1,104 from $886 in a note on Monday.",
    "url": "https://finnhub.io/api/news?id=21c5b23e21e602fbff1165b8b0761d56d13536f8ad36eac3aa40657b62ec5de2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762797480,
      "headline": "Eli Lilly Stock on Pace for a New High. The Zepbound Maker Just Got a Big Upgrade.",
      "id": 137396560,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of  Eli Lilly  have not only bounced back from last week’s lows but have also surged to new highs as Wall Street digs into the implications of the company’s deal with the U.S. government.  Lilly stock was up 4.8% at $969.14, putting it on pace for a record closing high, according to Dow Jones Market Data.  Leerink Partners analyst David Risinger upgraded shares to Outperform from Market Perform and raised his price target to $1,104 from $886 in a note on Monday.",
      "url": "https://finnhub.io/api/news?id=21c5b23e21e602fbff1165b8b0761d56d13536f8ad36eac3aa40657b62ec5de2"
    }
  },
  {
    "ts": null,
    "headline": "Why Eli Lilly (LLY) Stock Is Trading Up Today",
    "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 4.9% in the afternoon session after Leerink Partners upgraded the stock to Outperform from Market Perform and significantly raised its price target.",
    "url": "https://finnhub.io/api/news?id=faac3e8742bcfd21265d42bf024fb948506ed742507b2a5e522103a6cd8f867b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762796177,
      "headline": "Why Eli Lilly (LLY) Stock Is Trading Up Today",
      "id": 137437660,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 4.9% in the afternoon session after Leerink Partners upgraded the stock to Outperform from Market Perform and significantly raised its price target.",
      "url": "https://finnhub.io/api/news?id=faac3e8742bcfd21265d42bf024fb948506ed742507b2a5e522103a6cd8f867b"
    }
  },
  {
    "ts": null,
    "headline": "Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?",
    "summary": "Alto Neuroscience, Autolus Therapeutics, Ascendis Pharma and Immuneering are gearing up to report Q3 results that could top expectations.",
    "url": "https://finnhub.io/api/news?id=877f405f48fd14d51729b48bb9c43bc2eb55d994dcd1734202be682688a5bfe5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762791660,
      "headline": "Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?",
      "id": 137396561,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Alto Neuroscience, Autolus Therapeutics, Ascendis Pharma and Immuneering are gearing up to report Q3 results that could top expectations.",
      "url": "https://finnhub.io/api/news?id=877f405f48fd14d51729b48bb9c43bc2eb55d994dcd1734202be682688a5bfe5"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly inks new AI deal, Tyson tops Q4 earnings estimates",
    "summary": "Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Plug Power (PLUG) suspending its loan-guarantee initiative amid liquidity challenges, Eli Lilly's (LLY) new AI deal with Insilico Medicine, and Tyson Foods (TSN) topping fourth quarter adjusted earnings estimates. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
    "url": "https://finnhub.io/api/news?id=43dba8e05442e59d53a3276381ecff3e57a9e6e6dfc91823d4d21bc0a9c88a0d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762791225,
      "headline": "Eli Lilly inks new AI deal, Tyson tops Q4 earnings estimates",
      "id": 137396562,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Plug Power (PLUG) suspending its loan-guarantee initiative amid liquidity challenges, Eli Lilly's (LLY) new AI deal with Insilico Medicine, and Tyson Foods (TSN) topping fourth quarter adjusted earnings estimates. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
      "url": "https://finnhub.io/api/news?id=43dba8e05442e59d53a3276381ecff3e57a9e6e6dfc91823d4d21bc0a9c88a0d"
    }
  },
  {
    "ts": null,
    "headline": "What’s Next for Novo Nordisk?",
    "summary": "After losing out to Pfizer for a weight-loss drug startup, Novo Nordisk will now have to count more heavily on its own research labs for new drugs, even as it’s likely to continue to pursue other deals.  Novo Nordisk’s near-term focus is to launch a pill form of Wegovy, the popular weight-loss drug it first launched in 2021 as a weekly injectable.  Novo Nordisk has applied for Food and Drug Administration approval, and expects a decision by year end.",
    "url": "https://finnhub.io/api/news?id=88be7d0fe0dac9fb2bce34aab3f251b0cb63d3597e5272561b3752fb33d89530",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762788966,
      "headline": "What’s Next for Novo Nordisk?",
      "id": 137396563,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "After losing out to Pfizer for a weight-loss drug startup, Novo Nordisk will now have to count more heavily on its own research labs for new drugs, even as it’s likely to continue to pursue other deals.  Novo Nordisk’s near-term focus is to launch a pill form of Wegovy, the popular weight-loss drug it first launched in 2021 as a weekly injectable.  Novo Nordisk has applied for Food and Drug Administration approval, and expects a decision by year end.",
      "url": "https://finnhub.io/api/news?id=88be7d0fe0dac9fb2bce34aab3f251b0cb63d3597e5272561b3752fb33d89530"
    }
  },
  {
    "ts": null,
    "headline": "Will Lower GLP-1 Prices Undermine Novo Nordisk's Near-Term Outlook?",
    "summary": "NVO's new U.S. pricing deal for Ozempic and Wegovy expands access but adds uncertainty to its growth and profit outlook.",
    "url": "https://finnhub.io/api/news?id=dae324fcea999fe886ad4da753741ab7caeba0a7b3d3e09ab812a2a3f8571c9e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762788360,
      "headline": "Will Lower GLP-1 Prices Undermine Novo Nordisk's Near-Term Outlook?",
      "id": 137396564,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVO's new U.S. pricing deal for Ozempic and Wegovy expands access but adds uncertainty to its growth and profit outlook.",
      "url": "https://finnhub.io/api/news?id=dae324fcea999fe886ad4da753741ab7caeba0a7b3d3e09ab812a2a3f8571c9e"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk shares rise on investor relief after it exits Metsera bid",
    "summary": "STORY: Shares in Novo Nordisk rose on Monday (November 10).Investors bought in after the Wegovy maker lost out to Pfizer in a $10 billion bidding war for U.S. biotech Metsera.Market watchers saw its offer as too complex.The Danish drugmaker has also come under more pressure over governance.That after Norway's sovereign wealth fund said it would abstain when Novo shareholders vote this week on a new board.Pfizer said late Friday it had secured a deal for obesity drug developer Metsera.It was a setback for Novo as it tries to compete with rival Eli Lilly in the weight-loss drug market.Novo had started the bidding war in late October with an unsolicited offer a month after Metsera and Pfizer agreed a deal.The U.S. Federal Trade Commission told Novo and Metsera last week their proposed deal risked breaking U.S. antitrust laws.Metsera cited the antitrust concerns in rejecting Novo's bid.The Danish drugmaker confirmed Saturday it would withdraw from the race.Novo's shares were up 2.6% by Monday afternoon.The stock has lost more than 70% of its value since June last year.",
    "url": "https://finnhub.io/api/news?id=6b54538828a6fe802a9e40f19ea645845b43b570d8b839ee49ae756a45d90606",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762786630,
      "headline": "Novo Nordisk shares rise on investor relief after it exits Metsera bid",
      "id": 137394828,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "STORY: Shares in Novo Nordisk rose on Monday (November 10).Investors bought in after the Wegovy maker lost out to Pfizer in a $10 billion bidding war for U.S. biotech Metsera.Market watchers saw its offer as too complex.The Danish drugmaker has also come under more pressure over governance.That after Norway's sovereign wealth fund said it would abstain when Novo shareholders vote this week on a new board.Pfizer said late Friday it had secured a deal for obesity drug developer Metsera.It was a setback for Novo as it tries to compete with rival Eli Lilly in the weight-loss drug market.Novo had started the bidding war in late October with an unsolicited offer a month after Metsera and Pfizer agreed a deal.The U.S. Federal Trade Commission told Novo and Metsera last week their proposed deal risked breaking U.S. antitrust laws.Metsera cited the antitrust concerns in rejecting Novo's bid.The Danish drugmaker confirmed Saturday it would withdraw from the race.Novo's shares were up 2.6% by Monday afternoon.The stock has lost more than 70% of its value since June last year.",
      "url": "https://finnhub.io/api/news?id=6b54538828a6fe802a9e40f19ea645845b43b570d8b839ee49ae756a45d90606"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Lunch: Generative AI Powers October E-Commerce Spending",
    "summary": "Adobe (ADBE) says U.S. online spending rose 8.2% year-over-year in October to $88.7 billion.",
    "url": "https://finnhub.io/api/news?id=dce4f4231faca8f9bae441f731fdbb91b49bee3e3629e999aca01894e710bf46",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762786428,
      "headline": "Wall Street Lunch: Generative AI Powers October E-Commerce Spending",
      "id": 137400733,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2227981382/image_2227981382.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Adobe (ADBE) says U.S. online spending rose 8.2% year-over-year in October to $88.7 billion.",
      "url": "https://finnhub.io/api/news?id=dce4f4231faca8f9bae441f731fdbb91b49bee3e3629e999aca01894e710bf46"
    }
  },
  {
    "ts": null,
    "headline": "Coinbase upgraded, Six Flags downgraded: Wall Street's top analyst calls",
    "summary": "Coinbase upgraded, Six Flags downgraded: Wall Street's top analyst calls",
    "url": "https://finnhub.io/api/news?id=2402c3cf2519f2dd52e9c3462849a73b98c8aae724fea1663cff98bcdb3a0ee7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762785549,
      "headline": "Coinbase upgraded, Six Flags downgraded: Wall Street's top analyst calls",
      "id": 137394741,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Coinbase upgraded, Six Flags downgraded: Wall Street's top analyst calls",
      "url": "https://finnhub.io/api/news?id=2402c3cf2519f2dd52e9c3462849a73b98c8aae724fea1663cff98bcdb3a0ee7"
    }
  },
  {
    "ts": null,
    "headline": "Insilico and Lilly Enter a Research & Licensing Collaboration to Advance AI-Driven Drug Discovery",
    "summary": "Insilico Medicine (\"Insilico\"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced a research collaboration with Eli Lilly (\"Lilly\") that the two parties will combine Insilico's state-of-the-art Pharma.AI platforms with Lilly's development and disease expertise to jointly discover and advance innovative therapies.",
    "url": "https://finnhub.io/api/news?id=5fc794a94b1d04b650b0e3a08557e149555edc7e103b0b2146ab4cf68ef0f464",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762785180,
      "headline": "Insilico and Lilly Enter a Research & Licensing Collaboration to Advance AI-Driven Drug Discovery",
      "id": 137394831,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Insilico Medicine (\"Insilico\"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced a research collaboration with Eli Lilly (\"Lilly\") that the two parties will combine Insilico's state-of-the-art Pharma.AI platforms with Lilly's development and disease expertise to jointly discover and advance innovative therapies.",
      "url": "https://finnhub.io/api/news?id=5fc794a94b1d04b650b0e3a08557e149555edc7e103b0b2146ab4cf68ef0f464"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly upgraded at Leerink on ’multiple waves’ of obesity drug adoption",
    "summary": "Investing.com -- Eli Lilly shares were upgraded to Outperform at Leerink Partners, which cited “multiple waves of obesity treatment adoption drivers” and raised its price target to $1,104 from $886.",
    "url": "https://finnhub.io/api/news?id=4a99d7b4385da23e82d17b4089ead46d8d8334a3f1de08077a2679c6b8cc4ef0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762784343,
      "headline": "Eli Lilly upgraded at Leerink on ’multiple waves’ of obesity drug adoption",
      "id": 137394832,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- Eli Lilly shares were upgraded to Outperform at Leerink Partners, which cited “multiple waves of obesity treatment adoption drivers” and raised its price target to $1,104 from $886.",
      "url": "https://finnhub.io/api/news?id=4a99d7b4385da23e82d17b4089ead46d8d8334a3f1de08077a2679c6b8cc4ef0"
    }
  },
  {
    "ts": null,
    "headline": "Queer Eye's Tan France helps unthread obesity bias as part of Zepbound's (tirzepatide) 'Changing the Thread Collection'",
    "summary": "For Tan France, clothing has always been about more than appearance – it's about self-expression. As a stylist and advocate, he's spent years helping people express their individuality through what they wear. But he's also seen first-hand the stigma carried by people living with obesity, amplified by society's misunderstanding of the science behind the chronic disease and the persistent belief that obesity is simply a failure of willpower.",
    "url": "https://finnhub.io/api/news?id=19ea28c541d886b2cd207ee702f6a3f435c5e4fbe76cb91d8fcbbfe375a77f64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762783920,
      "headline": "Queer Eye's Tan France helps unthread obesity bias as part of Zepbound's (tirzepatide) 'Changing the Thread Collection'",
      "id": 137394834,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "For Tan France, clothing has always been about more than appearance – it's about self-expression. As a stylist and advocate, he's spent years helping people express their individuality through what they wear. But he's also seen first-hand the stigma carried by people living with obesity, amplified by society's misunderstanding of the science behind the chronic disease and the persistent belief that obesity is simply a failure of willpower.",
      "url": "https://finnhub.io/api/news?id=19ea28c541d886b2cd207ee702f6a3f435c5e4fbe76cb91d8fcbbfe375a77f64"
    }
  },
  {
    "ts": null,
    "headline": "Here Are Monday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Alphabet, Apple, Eli Lilly, CarMax, HubSpot, and More",
    "summary": "Pre-Market Stock Futures: The futures are trading higher as the new week begins, with most investors and traders relieved that last week has come to a close. Hopes that an end to the Government shutdown in Congress is driving the futures higher this morning. The same mantra that was chanted last week — AI/Bubble, stocks ... Here Are Monday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Alphabet, Apple, Eli Lilly, CarMax, HubSpot, and More",
    "url": "https://finnhub.io/api/news?id=f7ec01129817f3397dc80aca48da63aee5b5135dd7d6e52a2d9f3c77ef6f54bd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762783862,
      "headline": "Here Are Monday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Alphabet, Apple, Eli Lilly, CarMax, HubSpot, and More",
      "id": 137394702,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pre-Market Stock Futures: The futures are trading higher as the new week begins, with most investors and traders relieved that last week has come to a close. Hopes that an end to the Government shutdown in Congress is driving the futures higher this morning. The same mantra that was chanted last week — AI/Bubble, stocks ... Here Are Monday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Alphabet, Apple, Eli Lilly, CarMax, HubSpot, and More",
      "url": "https://finnhub.io/api/news?id=f7ec01129817f3397dc80aca48da63aee5b5135dd7d6e52a2d9f3c77ef6f54bd"
    }
  },
  {
    "ts": null,
    "headline": "Does Trump's MFN Policy Put Pharma ETFs in the Crosshairs?",
    "summary": "With Trump's MFN policy cutting U.S. drug prices, will Pharma ETFs such as IHE, heavily weighted toward Eli Lilly and Novo Nordisk, lose momentum?",
    "url": "https://finnhub.io/api/news?id=16a7a39cbe1e3d6a77b7a44f7c1022483a87f9ccad15040db0e2e6567d3ce4e8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762778820,
      "headline": "Does Trump's MFN Policy Put Pharma ETFs in the Crosshairs?",
      "id": 137394837,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "With Trump's MFN policy cutting U.S. drug prices, will Pharma ETFs such as IHE, heavily weighted toward Eli Lilly and Novo Nordisk, lose momentum?",
      "url": "https://finnhub.io/api/news?id=16a7a39cbe1e3d6a77b7a44f7c1022483a87f9ccad15040db0e2e6567d3ce4e8"
    }
  },
  {
    "ts": null,
    "headline": "Leerink Partners Upgrades Eli Lilly and (LLY)",
    "summary": "Leerink Partners Upgrades Eli Lilly and (LLY)",
    "url": "https://finnhub.io/api/news?id=71d8c209beb216f380e50eb33abd376e8db66d6f8a7198658d4e0e58b02aa3c5",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762776158,
      "headline": "Leerink Partners Upgrades Eli Lilly and (LLY)",
      "id": 137394018,
      "image": "",
      "related": "LLY",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=71d8c209beb216f380e50eb33abd376e8db66d6f8a7198658d4e0e58b02aa3c5"
    }
  },
  {
    "ts": null,
    "headline": "MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology",
    "summary": "LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced a broad strategic collaboration in the area of ophthalmology with Eli Lilly and Company (“Lilly”). MeiraGTx will grant Lilly worldwide exclusive rights to its AAV-AIPL1 program for treatment of one of the most severe inherited retinopathies, Leber congenital amaurosis 4 (LCA4) owing to genetic deficiency of Aryl-hydrocarbo",
    "url": "https://finnhub.io/api/news?id=7c517bc834370c6b15127236f72accb31c86cf889a762cb3540760329241297b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762776000,
      "headline": "MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology",
      "id": 137394839,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced a broad strategic collaboration in the area of ophthalmology with Eli Lilly and Company (“Lilly”). MeiraGTx will grant Lilly worldwide exclusive rights to its AAV-AIPL1 program for treatment of one of the most severe inherited retinopathies, Leber congenital amaurosis 4 (LCA4) owing to genetic deficiency of Aryl-hydrocarbo",
      "url": "https://finnhub.io/api/news?id=7c517bc834370c6b15127236f72accb31c86cf889a762cb3540760329241297b"
    }
  },
  {
    "ts": null,
    "headline": "Did Walmart's (WMT) New Healthcare and Logistics Moves Just Shift Its Investment Narrative?",
    "summary": "Walmart recently expanded its health and wellness offerings by partnering with Eli Lilly to provide direct-to-consumer access for the weight-loss drug Zepbound in its pharmacies, while also integrating GOFO's nationwide logistics services to strengthen its e-commerce marketplace delivery capabilities. These collaborations underscore Walmart’s drive to enhance healthcare access and delivery efficiency, reflecting a multi-faceted approach to digital transformation and marketplace...",
    "url": "https://finnhub.io/api/news?id=c75195cf7da072756bccc545b97e890893de28f88602af8b7e9723f428f0bd87",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762773224,
      "headline": "Did Walmart's (WMT) New Healthcare and Logistics Moves Just Shift Its Investment Narrative?",
      "id": 137394840,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Walmart recently expanded its health and wellness offerings by partnering with Eli Lilly to provide direct-to-consumer access for the weight-loss drug Zepbound in its pharmacies, while also integrating GOFO's nationwide logistics services to strengthen its e-commerce marketplace delivery capabilities. These collaborations underscore Walmart’s drive to enhance healthcare access and delivery efficiency, reflecting a multi-faceted approach to digital transformation and marketplace...",
      "url": "https://finnhub.io/api/news?id=c75195cf7da072756bccc545b97e890893de28f88602af8b7e9723f428f0bd87"
    }
  },
  {
    "ts": null,
    "headline": "Novo's $1,349 Shot Just Got Squeezed: Is Lilly Winning the Weight-Loss War?",
    "summary": "Novo Nordisk is under pressure from cheap copycats, a Trump pricing deal, and Lilly's fast-growing Zepbound juggernaut.",
    "url": "https://finnhub.io/api/news?id=35c3322c6a2f519b25d89af02fa558b2e8012fd970513e15383a34d803d1c550",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762772787,
      "headline": "Novo's $1,349 Shot Just Got Squeezed: Is Lilly Winning the Weight-Loss War?",
      "id": 137394841,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk is under pressure from cheap copycats, a Trump pricing deal, and Lilly's fast-growing Zepbound juggernaut.",
      "url": "https://finnhub.io/api/news?id=35c3322c6a2f519b25d89af02fa558b2e8012fd970513e15383a34d803d1c550"
    }
  },
  {
    "ts": null,
    "headline": "SanegeneBio and Lilly sign RNAi licence deal for metabolic diseases",
    "summary": "SanegeneBio is responsible for discovering and identifying optimised RNAi molecules for each programme through its LEAD platform.",
    "url": "https://finnhub.io/api/news?id=d03baa849c9a253fd2137799c53235f4f2a7907433be5d15688d4fce0e9c96ac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762767271,
      "headline": "SanegeneBio and Lilly sign RNAi licence deal for metabolic diseases",
      "id": 137394842,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "SanegeneBio is responsible for discovering and identifying optimised RNAi molecules for each programme through its LEAD platform.",
      "url": "https://finnhub.io/api/news?id=d03baa849c9a253fd2137799c53235f4f2a7907433be5d15688d4fce0e9c96ac"
    }
  },
  {
    "ts": null,
    "headline": "Lilly picks up an eye gene therapy in deal with MeiraGTx",
    "summary": "The alliance extends a deal streak in genetic medicine for Lilly and hands the company rights to an experimental treatment for an ultra-rare form of childhood blindness.",
    "url": "https://finnhub.io/api/news?id=155afd6ff41cbd22f1b019a775a41469b84646a93509134fe09a316f25db1252",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762757460,
      "headline": "Lilly picks up an eye gene therapy in deal with MeiraGTx",
      "id": 137394843,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The alliance extends a deal streak in genetic medicine for Lilly and hands the company rights to an experimental treatment for an ultra-rare form of childhood blindness.",
      "url": "https://finnhub.io/api/news?id=155afd6ff41cbd22f1b019a775a41469b84646a93509134fe09a316f25db1252"
    }
  },
  {
    "ts": null,
    "headline": "Walmart (WMT): Evaluating Valuation as Health and E-Commerce Moves Drive Analyst Optimism",
    "summary": "Walmart (WMT) is making headlines with several strategic moves, including a major collaboration to provide Eli Lilly’s Zepbound obesity treatment at its pharmacies. These initiatives highlight the company’s expanding role in healthcare and its enhanced e-commerce capabilities. See our latest analysis for Walmart. Walmart’s momentum is clearly building, fueled by a run of retail partnerships, digital health launches, and strategic logistics moves that continue to keep it in the spotlight. The...",
    "url": "https://finnhub.io/api/news?id=5def2cdd9b3783ffa7b042bf56da29b58c9b6f97cd0930eae1d55080398618e1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762754691,
      "headline": "Walmart (WMT): Evaluating Valuation as Health and E-Commerce Moves Drive Analyst Optimism",
      "id": 137392491,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Walmart (WMT) is making headlines with several strategic moves, including a major collaboration to provide Eli Lilly’s Zepbound obesity treatment at its pharmacies. These initiatives highlight the company’s expanding role in healthcare and its enhanced e-commerce capabilities. See our latest analysis for Walmart. Walmart’s momentum is clearly building, fueled by a run of retail partnerships, digital health launches, and strategic logistics moves that continue to keep it in the spotlight. The...",
      "url": "https://finnhub.io/api/news?id=5def2cdd9b3783ffa7b042bf56da29b58c9b6f97cd0930eae1d55080398618e1"
    }
  },
  {
    "ts": null,
    "headline": "2 Growth Stocks with All-Star Potential and 1 We Question",
    "summary": "Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.",
    "url": "https://finnhub.io/api/news?id=46145df140c164f9b5732254a5ab2becc86e5957cf0531b733629b1b2af110c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762749232,
      "headline": "2 Growth Stocks with All-Star Potential and 1 We Question",
      "id": 137394844,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.",
      "url": "https://finnhub.io/api/news?id=46145df140c164f9b5732254a5ab2becc86e5957cf0531b733629b1b2af110c5"
    }
  }
]